Document is current
Any future updates will be listed below
-
Authors
Stanevich, O. V. http://orcid.org/0000-0002-6894-6121
Fomina, D. S.
Bakulin, I. G.
Galeev, S. I.
Bakin, E. A.
Belash, V. A.
Kulikov, A. N.
Lebedeva, A. A.
Lioznov, D. A.
Polushin, Yu. S.
Shlyk, I. V.
Vorobyev, E. A.
Vorobyeva, S. V.
Surovceva, T. V.
Bakulina, N. V.
Lysenko, M. A.
Moiseev, I. S.
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04337359 at ClinicalTrials.govDocuments that mention this clinical trial
Ruxolitinib versus dexamethasone in hospitalized adults with COVID-19: multicenter matched cohort study
https://doi.org/10.1186/s12879-021-06982-z
-
Funding
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation (Managed Acces Program (MAP))
The Ministry of Science and Higher Education of the Russian Federation (Agreement № 075-15-2021-1086, contract № RF----193021X0015)
- License Information
-
More Information
Article History
Received: 3 May 2021
Accepted: 15 December 2021
First Online: 22 December 2021
Declarations
:
: We confirm all relevant ethical guidelines have been followed, and any necessary IRB and ethics committee approvals have been obtained.The study protocol was submitted and approved by the biomedical ethics committee of I.P. Pavlov First Saint Petersburg State Medical University.Informed written consent from all participants was obtained during the study.All necessary and appropriate institutional forms from patients were archived.
: Not applicable.
: I.S.M. had received travel grants from MSD, Novartis, Pfizer, Celgene, Takeda, BMS, consulting fees from Novartis and Celgene, lecturer fees from Novartis, Takeda and Johnson&Johnson.
